Lifecore Biomedical Stock Forecast
NASDAQ: LFCRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 10:15 AM ET
LFCR analyst consensus
Consensus (4 analysts)
hold
Avg. price target
$6.28-2.41%
- Strong buy 0
- Buy 0
- Hold 4
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 4 Wall Street analysts covering Lifecore Biomedical (2026-10-08), 0 rate the stock a buy or strong buy, 4 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "hold". The average 12-month price target is $6.28, with a high estimate of $6.28 and a low estimate of $6.28. The average target implies downside of 2.4% from the current price of $6.44.
The spread between the highest and lowest targets is 0.0%, a relatively narrow range. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for LFCR.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 0 | 0% |
| Buy | 0 | 0% |
| Hold | 4 | 100% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-08.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $6.28 | -2.41% |
| Average target | $6.28 | -2.41% |
| High target | $6.28 | -2.41% |